Mismatch Repair Deficient Cancers

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2020-03-02
Clinical Trial Update: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor [Phase 2]
Phase 2 trial evaluating the combination of Anlotinib with AK105 injections in MSI-H or dMMR advanced solid tumors.